Back to RecallTracker
Health Canada Health products

Authorization of Casirivimab and Imdevimab with English-only Labels for Use in Relation to the COVID-19 Pandemic

Issued July 30, 2021
Issue
Casirivimab and imdevimab (administered together) were authorized for use in relation to the COVID-19 pandemic, in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 . To provide earlier access to the product in the context of the global pandemic, Hoffmann-La Roche will distribute one standard global pandemic packaging with English-only labelling.
Hazard description
Product safety